The second generation of DPIs have become either established on the market or are a significant way along the approval process. These have been a great success story in improving inhaled drug delivery. However, we now have to tackle the technical and regulatory issues with ‘generic’ inhalers and their approval. The development of triple therapies is well underway, these bring about their own challenges of formulation and bioequivalence. Dr Orest Lastow is the co-founder and CEO of Iconovo AB. He is responsible for the development of Iconovo’s inhalation device platform.